Analytical Data
-
基因名
IFN-beta
- Application
-
生物活性
Measured in a cell cytotoxicity assay using TF-1 cells. The ED50 for this effect is 0.29-1.17 ng/mL, corresponding to a specific activity of 8.53×105~3.41×106 units/mg.
-
别名
IFNB1；IFB；IFNB；Interferon beta
-
种属
Human
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01574
-
表达区间
22-187aa
-
氨基酸序列
MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
-
分子量
30 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
IFNB1, or Interferon beta-1, is a crucial cytokine involved in the immune response, primarily recognized for its antiviral properties and role in modulating inflammation. Research into IFNB1 recombinant protein began in the context of its therapeutic potentials, especially for conditions like multiple sclerosis (MS) and certain viral infections. Given its ability to enhance the antiviral state of cells and regulate immune functions, scientists have focused on its recombinant form to overcome the challenges associated with natural sources, including variable potency and stability. Recombinant IFNB1 has been developed using various expression systems such as bacterial, yeast, and mammalian cell lines, allowing for more consistent production and improved bioactivity. These advances have enabled extensive clinical studies to evaluate IFNB1’s efficacy and safety profiles, leading to its approval as a treatment for MS and other inflammatory diseases. Moreover, ongoing research aims to optimize its formulation, delivery methods, and explore its potential in combination therapies, thus enhancing its therapeutic effectiveness. The pursuit of understanding IFNB1's mechanisms of action continues to provide insights, influencing the development of novel immunotherapies and expanding its applications in clinical settings.
